SEC Form 4 · accession 0001193805-18-000189
ADMA BIOLOGICS, INC. · ADMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Lenz
Officer — VP, CFO
Period of report
Feb 9, 2018
Accepted (ET)
Feb 13, 2018 · 9:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001368514
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $3.71 | Feb 9, 2018 | A | 150,000 | A | — | Feb 9, 2028 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022.